´ëÇѺÎÀÎÁ¾¾çÇÐȸ 2022 Á¦ 37Â÷ Ãá°èÇмú´ëȸ : 2022-04-15 |
|
´ëÇѺÎÀÎÁ¾¾çÇÐȸ 2022 Á¦ 37Â÷ Ãá°èÇмú´ëȸ : 2022-04-15 ±³À°ÀÏÀÚ : 2022-04-15 ±³À°Àå¼Ò : Á¦ÁÖ ¸ÞÁ¾ ±Û·¡µå È£ÅÚ ±³À°ÁÖÁ¦ : 2022 Á¦ 37Â÷ Ãá°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ ´ã´çÀÚ : ÀÌÀº¿µ ¿¬¶ôó : 02-512-5915 À̸ÞÀÏ : office@sgo,or.kr ±³À°Á¾·ù : »êºÎÀΰú Âü¼®¿¹»óÀοø : 200¸í Èñ¸ÁÆòÁ¡ : 6Á¡ Áö¿ª : Á¦ÁÖƯº°ÀÚÄ¡µµ ±³À°½Ã°£ : 12 ½Ã°£ 10ºÐ ¼¼ºÎ¼ö°·á : 80,000¿ø ºñ°í (»çÀüµî·Ï)Àü¹®ÀÇ 80,000 Àü°øÀÇ,60,000 ¿¬±¸¿ø,°£È£»ç 40,000 ÁÂÀå,¿¬ÀÚ,Åä·ÐÀÚ,¸¸65¼¼ÀÌ»ó ¹«·á (ÇöÀåµî·Ï) Àü¹®ÀÇ 90,000 Àü°øÀÇ,70,000 ¿¬±¸¿ø,°£È£»ç 50,000 ÁÂÀå,¿¬ÀÚ,Åä·ÐÀÚ,¸¸65¼¼ÀÌ»ó ¹«·á ±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ ±âŸ 04-15 ÄÁº¥¼Ç Ȧ 08:30~08:50 Registration ÀÌ´ë¿ì(´ëÇѺÎÀÎÁ¾¾çÇÐȸ »ç¹«ÃÑÀå) ±âŸ 04-15 ÄÁº¥¼Ç Ȧ 08:50~09:00 °³È¸»ç ¹× ¸í¿¹È¸¿øÁõ ¼ö¿© ±è¿µÅ (´ëÇѺÎÀÎÁ¾¾çÇÐȸ ȸÀå) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 09:00~09:20 Recurrent ovarian cancer: when does surgery make a difference? Ginger J. Gardner(Memorial Sloan Kettering Cancer Center, USA) Åä·Ð 04-15 ÄÁº¥¼Ç Ȧ 09:20~09:25 Desiginated discussion ÀÓ°¡¿ø (µ¿±¹ÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 09:25~09:45 Overcoming homologous recombination proficiency in ovarian cancer Aikou Okamoto(Jikei University, Japan) Åä·Ð 04-15 ÄÁº¥¼Ç Ȧ 09:45~09:50 Desiginated discussion ÃÖÀ±Áø(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 09:50~10:10 Recent progress of precision medicine in ovarian cancer Andreas du Bois(Kliniken Essen-Mitte, Germany) Åä·Ð 04-15 ÄÁº¥¼Ç Ȧ 10:10~10:15 Desiginated discussion ¹Ú¼öÁø(¼¿ïÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 10:15~10:35 Bio- and GenomeBank Denmark (RBGB) including the danish cancerbiobank Estrid Hoegdall(University of Copenhagen, Denmark) Åä·Ð 04-15 ÄÁº¥¼Ç Ȧ 10:35~10:40 Desiginated discussion À¯»ó¿µ(¿øÀڷº´¿ø) ÈÞ½Ä 04-15 10:40~11:00 Coffee break () ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 11:00~11:10 Lymphadenectomy in clinically early epitheLial ovarian cancer and survival analysis: A multicenter study from the Gynecologic Oncology Research Investigators coLLaborAtion (GORILLA) group (GORILLA-3002) ¾çÀºÁ¤(°Ç±¹ÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 11:10~11:20 Optimum selection criteria for secondary cytoreductive surgery in patients with recurrent ovarian cancer: A multicenter study from the Gynecologic Oncology Research Investigators coLLaborAtion (GORILLA) group (GORILLA-3001) ¼ÕÁÖÇõ(¾ÆÁÖÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 11:20~11:30 Selection Criteria for Omitting interval debulking suRgery after nEoadjuvant chemotherapy for advanced high-grade serous carcinoma of the ovary: KGOG OVsurg-2016/SCORE study ¹Ú¼öÁø(¼¿ïÀÇ´ë) Åä·Ð 04-15 ÄÁº¥¼Ç Ȧ 11:30~11:40 Designated discussion |%$| ÀÌ´ëÇü, ÀÌ¿ø¹«(¿¬¼¼ÀÇ´ë, ¿µ³²ÀÇ´ë, ÇѾçÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 11:40~11:50 A nomogram to predict anastomotic leakage after resection of the rectosigmoid colon in primary ovarian cancer ±èÁöÇö(±¹¸³¾Ï¼¾ÅÍ) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 11:50~12:00 Optimal management of platinum-sensitive relapsed ovarian clear cell carcinoma: a multi-center study in Korea ±è¼¼ÀÍ(¼¿ïÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 12:00~12:10 Prognostic impact of erythropoietin-stimulating agents during front-line chemotherapy in patients with ovarian cancer: a Korean multicenter cohort study ½É½ÂÇõ(°Ç±¹ÀÇ´ë) Åä·Ð 04-15 ÄÁº¥¼Ç Ȧ 12:10~12:20 Designated discussion À̼±ÁÖ, ½ÅÁø¿ì, ³²ÀºÁö(°Ç±¹ÀÇ´ë, °¡ÃµÀÇ´ë, ¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 12:20~12:40 A new powder-type hemostatic agent in gynecologic oncologic surgical procedures ¹Ú¼ºÅÃ(ÇѸ²ÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 12:40~13:00 The incorporation of HPV testing for cervical cancer screening: The What, Why, and How? Warner K. Huh(University of Alabama at Birmingham, USA) ½Ä»ç 04-15 13:00~13:30 Lunch () ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 13:30~13:40 Clinicopathologic and protein markers distinguishing the ¡°polymerase epsilon exonuclease¡± from the ¡°copy number low¡± subtype of endometrial cancer ±è±âµ¿(¼¿ïÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 13:40~13:50 Ten-year survival for patients with epithelial ovarian cancer treated with consolidation hyperthermic intraperitoneal chemotherapy À¯Áö±Ù(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 13:50~14:00 Genome-based molecular classification and clinicopathological features in korean patients ÇÑ°æÈñ(Â÷ÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 14:10~14:10 Anticancer effect of fenbendazole according to drug delivery mode in ovarian cancer models ÀåÁö¼±(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 14:10~14:20 Open versus minimally invasive radical hysterectomy in early-stage cervical cancer with usual type adenocarcinoma and adenosquamous carcinoma: a two-center retrospective study with central pathology review ±è¿©·¡(¼¿ïÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 14:20~14:30 Development and validation of a prediction model for successful complete cytoreduction at primary cytoreductive surgery for advanced ovarian cancer by integrating of 18F-FDG PET/CT parameters and CA-125 ±èÁØȯ(¼¿ïÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 14:30~14:40 Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer ÀüÁ¤Àº(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 14:40~14:50 Evaluation of anti-cancer ecacy of siRNA targeting HPV16 E6 and E7 combined with cisplatin in cervical cancer cells xenograft mouse model ¹Ú¹ÎÁ¤(¿ï»êÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 14:50~15:00 Plasma-activated medium inhibits cancer stem cell-like properties and exhibits a synergistic effect in combination with cisplatin in ovarian cancer ±Çº´¼ö(°æÈñÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 15:00~15:10 Anti-cancer activity of cabozatinib and temozolomide and their effcacy for uterine leiomyosarcoma in a mouse xenograft model ³ëÁØÈ£(¼º±Õ°üÀÇ´ë) ÈÞ½Ä 04-15 15:10~15:30 Coffee break () ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 15:30~15:45 ÀÇ»çÀÇ ¼³¸íÀǹ«¿Í ÀÇ·áºÐÀï ÇöµÎ·û(¹ý¹«¹ýÀÎ ¼¼½Â) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 15:45~15:55 ¼ö¼úµ¿ÀǼ ¼Ò°³ ½É½ÂÇõ(°Ç±¹ÀÇ´ë) Åä·Ð 04-15 ÄÁº¥¼Ç Ȧ 15:55~16:05 Discussion ÀåÇϱÕ(°í·ÁÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 16:05~16:20 ±¹°¡¾Ï°ËÁø ÀڱðæºÎ¾Ï ¼±º°°Ë»ç¿¡¼ ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º DNA°Ë»çÀÇ ºñ¿ë-È¿°ú ºÐ¼® ¹ÚÀºÃ¶(¿¬¼¼ÀÇ´ë ¿¹¹æÀÇÇб³½Ç) Åä·Ð 04-15 ÄÁº¥¼Ç Ȧ 16:20~16:30 Discussion Á¤´ëÈÆ(ÀÎÁ¦ÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 1 13:30~13:40 Effect of post-operative hormone replacement therapy on survival in women with ovarian cancer À̹æÇö(ÀÎÇÏÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 1 13:40~13:50 Effcacy and potential pitfalls of pre-operative PET-CT in endometrial cancer patients undergoing one-step and two-step sentinel lymph node mapping: is PET-CT negative really node negative? ±èÀ¯³ª(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 1 13:50~14:00 Survival outcomes from laparoscopic radical hysterectomy in conizationskipped, stage IB1 cervical cancer ÀÓÇöÁö(¼¿ïÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 1 14:00~14:10 Role of glycine decarboxylase in chemo-resistant ovarian cancer cells À̽¹Ì(°è¸íÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 1 14:10~14:20 Is minimally invasive surgery safe for cervical cancer patients with a diameter of less than 2 cm? °øÅ¿í(¾ÆÁÖÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 1 14:20~14:30 Incidence of cervical intraepithelial neoplasia in republic of korea: a nation-wide cross-sectional study 2009-2018 °æ¹Î¼±(ÇѸ²ÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 1 14:30~14:40 A phase II trial of docetaxel/cisplatin chemotherapy followed by pelvic radiation therapy in patients with high-risk endometrial carcinoma after staging surgery Á¶À±Á¤(¿ï»êÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 1 14:40~14:50 Role of klotho as a modulator of oxidative stress associated with ovarian tissue cryopreservation ÀÌ»óÈÆ(°í·ÁÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 1 14:50~15:00 Comparison of outcome of sentinel node biopsy vs. Lymphadenectomy in endometrial cancer: a propensity-matched data ÀÌ´ÙÇý(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 1 15:00~15:10 Enhanced susceptibility to cervical cancer in korean women with elevated serum gammaglutamyltransferase levels: a nationwide population-based cohort study ¼³¾Ö¶õ(°í·ÁÀÇ´ë) ÈÞ½Ä 04-15 15:10~15:30 Coffee break () ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 1 15:30~15:50 Biomarkers for molecular classification of endometrial cancer ±èÇö¼ö(¼º±Õ°üÀÇ´ë º´¸®Çб³½Ç) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 1 15:50~16:10 Biomarkers and HRD for ovarian cancer ±èÈ¿Áø(¼¿ïÀÇ´ë º´¸®Çб³½Ç) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 1 16:10~16:30 Biomarkers for uterine sarcoma and rare tumors Á¶ÈÁø(ÀÎÁ¦°üÀÇ´ë º´¸®Çб³½Ç) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 2 13:30~13:40 Prediction of platinum-based chemotherapy sensitivity for epithelial ovarian cancer by magnetic resonance-based radiomics ¼ÛÈñ°æ(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 2 13:40~13:50 Trends in incidence and survival of patients with vulvar cancer in an asian country: analysis of the korean central cancer registry 1999–2018 Á¶¼º½Ç(ÇѾçÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 2 13:50~14:00 Recurrence prediction of endometrial cancer patients with various machine learning technique ½Å¿ø±³(Ãæ³²ÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 2 14:00~14:10 Anti-tumor effects of lenvatinib plus anti-PD-1 in syngeneic murine cervical cancer models °Áö½Ä(¿ï»êÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 2 14:10~14:20 The expression of HOXA-AS3 induces tumor progression through the epithelial-mesenchymal transition pathway in epithelial ovarian cancer ¾î°æÁø(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 2 14:20~14:30 Clinical characteristics and desensitization protocol of chemotherapyinduced hypersensitivity reactions in patients with gynecologic cancer ±è½ÂÈ£(¿ï»êÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 2 14:30~14:40 Impact of neoadjuvant chemotherapy cycles in patients with advanced epithelial ovarian cancer: meta-analysis and systemic review Á¶Çö¿õ(°í·ÁÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 2 14:40~14:50 Identification of immune-related biomarkers associated with BRCA mutations in epithelial ovarian cancer ±èÈ¿¼±(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 2 14:50~15:00 Lymphedema in cervical cancer survivor: a nationwide cohort study À̼öÁ¤(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 2 15:00~15:10 Multiplexed immunohistochemistry for immune profiling in cervical cancer according to tumor budding status ±èÁ¾¹Ì(°æºÏÀÇ´ë) ÈÞ½Ä 04-15 15:10~15:30 Coffee break () ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 2 15:30~15:40 DKK3, downregulated in ovarian cancer, enhanced paclitaxel susceptibility by inhibiting the P-glycoprotein ÀÌÀºÁÖ(Áß¾ÓÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 2 15:40~15:50 Effect of quality control program in surgical management of early cervical cancer ±èº¸¶ó(ÀÌÈÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 2 15:50~16:00 CD8¥á+ dendritic cells enhance the antitumor and immune activities against syngeneic and orthotopic murine ovarian cancer models ³²¼ÒÇö(¿ï»êÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 2 16:00~16:10 Robotic single-site radical hysterectomy for early cervical cancer: a single center experience of 5 years ÀåűÔ(°è¸íÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 2 16:10~16:20 Prediction of lymphovascular space invasion in patients with endometrial cancer ±è»óÀÏ(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 04-15 Å©¸®½ºÅ» Ȧ 2 16:20~16:30 Neutrophil–lymphocyte and platelet–lymphocyte ratios in preoperative differential diagnosis of benign, borderline, and malignant ovarian tumors À¯Á¤¹Î(´ë±¸°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 04-15 ÄÁº¥¼Ç Ȧ 16:40~17:15 Endometrial cancer with suspicious lymph node metastasis ¹ÚÁ¤¿(¿ï»êÀÇ´ë) Åä·Ð 04-15 ÄÁº¥¼Ç Ȧ 17:15~17:20 Panel discussion ±èÅÂÈÆ, ÀÌÀ¯¿µ, ±è¹Ì°æ(¼¿ïÀÇ´ë, ¼º±Õ°üÀÇ´ë, ÀÌÈÀÇ´ë) ±âŸ 04-15 ÄÁº¥¼Ç Ȧ 17:20~17:20 Æóȸ»ç ±è¿µÅ (´ëÇѺÎÀÎÁ¾¾çÇÐȸ ȸÀå) |
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|